Peripheral Artery Disease Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest Drug Approvals by DelveInsight | Sanofi, Novartis, Hemostemix, Caladrius Biosciences, Bayer, AstraZeneca

Posted on
by

Peripheral Artery Disease Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest Drug Approvals by DelveInsight | Sanofi, Novartis, Hemostemix, Caladrius Biosciences, Bayer, AstraZeneca
DelveInsight’s “Peripheral Artery Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Peripheral Artery Disease.

DelveInsight’s “Peripheral Artery Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Peripheral Artery Disease, historical and forecasted epidemiology as well as the Peripheral Artery Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Peripheral Artery Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Peripheral Artery Disease Market Forecast

 

Some of the key facts of the Peripheral Artery Disease Market Report: 

  • The Peripheral Artery Disease market size was valued USD 3900 Million in 2022 and is anticipated to grow with a significant CAGR of 4% during the study period (2019-2032)
  • The analyst at DelveInsight predicted that in 2021, there would be 36,661,865 cases of PAD in the 7MM, citing several research and working from the assumptions. A little over 55% of cases were reported in the US, compared to little under 39% in the EU-5; Germany had the most instances of the EU-5 countries
  • There were 15,671,031 confirmed prevalent cases of PAD in 7MM in 2021. The US has the highest percentage of cases (around 61%) followed by the EU-5 and Japan
  • Cell treatments make up the majority of the new PAD pipeline. The highlighted emerging medicines are Human Acellular Vessel (HAV) by Humacyte, Hemostemix’s ACP-01, Ixaka’s REX-001, and Honedra by Caladrius Bioscience
  • Key Peripheral Artery Disease Companies: Sanofi, Ixaka Ltd (formerly known as Rexgenero), Hemostemix Inc., Caladrius Biosciences, Bayer, AstraZeneca, Novartis, Genfleet Therapeutics, Korea Otsuka Pharma, POLYSAN Scientific & Technological Pharma, Daiichi Sankyo, UMC Utrecht, Yuhan Corporation, TheraVasc Inc., Mercator MedSystems, Inc.,Lee’s Pharma, Forest Laboratories, and others
  • Key Peripheral Artery Disease Therapies: REX-001, ACP-01, Honedra, Rivaroxaban, Ticagrelor, LLG783, GFH312, Cilostazol, Probucol, L-arginine, clopidogrel (SR25990), edoxaban, Clopidogrel, Anplag, sodium nitrite, Dexamethasone, Propionyl-L-carnitine, nebivolol, and others
  • The Peripheral Artery Disease epidemiology based on gender analyzed that females are more afcted with PAD than males
  • The Peripheral Artery Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Peripheral Artery Disease pipeline products will significantly revolutionize the Peripheral Artery Disease market dynamics.

 

Peripheral Artery Disease Overview

A frequent circulatory issue, peripheral artery disease (also known as peripheral arterial disease), is characterised by reduced blood flow to the limbs due to artery narrowing. Legs or arms—typically the legs—do not receive adequate blood flow to meet demand in peripheral artery disease (PAD).Symptoms like claudication, or leg pain when walking, could result from this. In addition, critical limb ischemia, stroke, or heart attack may result from the severe PAD.

 

Get a Free sample for the Peripheral Artery Disease Market Report 

https://www.delveinsight.com/report-store/peripheral-artery-disease-pad-market

 

Peripheral Artery Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Peripheral Artery Disease Epidemiology Segmentation:

The Peripheral Artery Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Peripheral Artery Disease
  • Prevalent Cases of Peripheral Artery Disease by severity
  • Gender-specific Prevalence of Peripheral Artery Disease
  • Diagnosed Cases of Episodic and Chronic Peripheral Artery Disease

 

Download the report to understand which factors are driving Peripheral Artery Disease epidemiology trends @ Peripheral Artery Disease Epidemiology Forecast

 

Peripheral Artery Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Peripheral Artery Disease market or expected to get launched during the study period. The analysis covers Peripheral Artery Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Peripheral Artery Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Peripheral Artery Disease Therapies and Key Companies

  • REX-001: Ixaka Ltd (formerly known as Rexgenero)
  • ACP-01: Hemostemix Inc.
  • Honedra: Caladrius Biosciences
  • Rivaroxaban: Bayer
  • Ticagrelor: AstraZeneca
  • LLG783: Novartis
  • GFH312: Genfleet Therapeutics
  • Cilostazol, Probucol: Korea Otsuka Pharma
  • L-arginine: POLYSAN Scientific & Technological Pharma
  • clopidogrel (SR25990): Sanofi
  • edoxaban: Daiichi Sankyo
  • Clopidogrel: UMC Utrecht
  • Anplag: Yuhan Corporation
  • sodium nitrite: TheraVasc Inc.
  • Dexamethasone: Mercator MedSystems, Inc.
  • Propionyl-L-carnitine: Lee’s Pharma
  • nebivolol: Forest Laboratories

 

Discover more about therapies set to grab major Peripheral Artery Disease market share @ Peripheral Artery Disease Treatment Market

 

Scope of the Peripheral Artery Disease Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Peripheral Artery Disease Companies: Sanofi, Ixaka Ltd (formerly known as Rexgenero), Hemostemix Inc., Caladrius Biosciences, Bayer, AstraZeneca, Novartis, Genfleet Therapeutics, Korea Otsuka Pharma, POLYSAN Scientific & Technological Pharma, Daiichi Sankyo, UMC Utrecht, Yuhan Corporation, TheraVasc Inc., Mercator MedSystems, Inc.,Lee’s Pharma, Forest Laboratories, and others
  • Key Peripheral Artery Disease Therapies: REX-001, ACP-01, Honedra, Rivaroxaban, Ticagrelor, LLG783, GFH312, Cilostazol, Probucol, L-arginine, clopidogrel (SR25990), edoxaban, Clopidogrel, Anplag, sodium nitrite, Dexamethasone, Propionyl-L-carnitine, nebivolol, and others
  • Peripheral Artery Disease Therapeutic Assessment: Peripheral Artery Disease current marketed and Peripheral Artery Disease emerging therapies
  • Peripheral Artery Disease Market Dynamics: Peripheral Artery Disease market drivers and Peripheral Artery Disease market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Peripheral Artery Disease Unmet Needs, KOL’s views, Analyst’s views, Peripheral Artery Disease Market Access and Reimbursement 

 

To know more about Peripheral Artery Disease companies working in the treatment market, visit @ Peripheral Artery Disease Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Peripheral Artery Disease Market Report Introduction

2. Executive Summary for Peripheral Artery Disease

3. SWOT analysis of Peripheral Artery Disease

4. Peripheral Artery Disease Patient Share (%) Overview at a Glance

5. Peripheral Artery Disease Market Overview at a Glance

6. Peripheral Artery Disease Disease Background and Overview

7. Peripheral Artery Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Peripheral Artery Disease 

9. Peripheral Artery Disease Current Treatment and Medical Practices

10. Peripheral Artery Disease Unmet Needs

11. Peripheral Artery Disease Emerging Therapies

12. Peripheral Artery Disease Market Outlook

13. Country-Wise Peripheral Artery Disease Market Analysis (2019–2032)

14. Peripheral Artery Disease Market Access and Reimbursement of Therapies

15. Peripheral Artery Disease Market Drivers

16. Peripheral Artery Disease Market Barriers

17.  Peripheral Artery Disease Appendix

18. Peripheral Artery Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services